RenovoRx Announces Interim Phase III Data Demonstrating RenovoGem Delays Cancer Progression By Eight Months In Locally Advanced Pancreatic Cancer
Portfolio Pulse from Benzinga Newsdesk
RenovoRx announced interim Phase III data showing that RenovoGem delays cancer progression by eight months in locally advanced pancreatic cancer. The results also showed a six-month overall survival benefit with RenovoGem versus systemic chemotherapy, and a 65% reduction in adverse effects. This highlights RenovoGem's potential to change the treatment paradigm for locally advanced pancreatic cancer.
June 29, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RenovoRx's interim Phase III data for RenovoGem shows promising results in treating locally advanced pancreatic cancer, potentially changing the treatment paradigm.
The positive interim Phase III data for RenovoRx's RenovoGem indicates a potential breakthrough in the treatment of locally advanced pancreatic cancer. This could significantly increase the company's market share in the oncology sector, leading to potential growth in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100